Investment Case
Aedion Therapeutics presents a credible, scientifically grounded opportunity in infectious disease — built for institutional investors, strategic partners, and specialist healthcare funders.
Important Notice: This website does not constitute an offer of securities or a solicitation to invest in any fund or vehicle. Nothing on this site should be construed as investment advice or a recommendation to buy or sell any security. This information is provided for general background purposes only and is directed at sophisticated parties conducting their own independent assessment of Aedion Therapeutics.
Positioning
Investor Overview
Aedion Therapeutics is a biotechnology company established to build a globally structured dengue therapeutics platform. The company is founded on a simple premise: there is already meaningful scientific and clinical groundwork behind VMD55 — what has been missing is the legal structure, IP strategy, product standardisation, and disciplined development pathway needed to turn that work into a financeable, global asset.
Aedion holds global exclusive rights and supply to VMD55, and is advancing the programme through a credible regulatory and clinical pathway beginning in priority markets. The company is built to be the institution that transforms pioneering scientific work — including the foundational contribution of Professor Max Reynolds — into a professionally managed therapeutic programme with long-term strategic value.
What makes Aedion compelling is that it combines three features. First, it is highly focused: the company is built around a defined therapeutic opportunity in dengue — a disease with significant regional burden and continued unmet need. Second, it is grounded in prior clinical work: in a randomised, placebo-controlled Phase III trial in Indonesia, patients treated with MAC, the predecessor material to VMD55, cleared dengue virus significantly faster than placebo (p=0.013), and the material was well tolerated. Third, it is being structured from the outset for protection, execution, and scalability.
In practical terms, Aedion holds the global exclusive licence and supply for VMD55, is protecting and expanding the intellectual property around the programme, standardising the product to internationally credible quality standards, and building the regulatory and clinical package needed to unlock the next stage of value creation.
Aedion's ambition is not simply to own an asset. It is to build the leading therapeutics company focused on dengue — and over time, a broader platform in mosquito-borne viral disease.
In a randomised, double-blind, placebo-controlled trial (532 randomised, ~450 analysed per protocol), patients treated with MAC cleared dengue virus significantly faster than placebo (p=0.013), with an accompanying immunomodulatory signal. The material was well tolerated across three human studies. The mechanism by which this occurs is not yet established: in-vitro work demonstrates direct virucidal activity, but only at concentrations far above those achievable by oral dosing, and a host-response mechanism remains a hypothesis. Establishing the mechanism, and demonstrating chemical continuity between the current material and the material used in 2013, are the two objectives of our current programme.
Results pertain to the predecessor compound to VMD55 and do not constitute regulatory approval of VMD55. VMD55 is advancing through an independent regulatory and clinical pathway. Chemical continuity between VMD55 and the trial material has not yet been established.
Why Now
The window to establish a globally structured, exclusively held dengue antiviral programme at this stage — with the scientific foundation already in place — is narrow. Dengue incidence is accelerating globally, regulatory interest in antivirals is increasing, and the existing prior clinical work provides a meaningful head start over any new entrant.
Aedion is at the point of finalising its rights structure and completing the foundational work that precedes the next clinical milestone. Investors who engage now participate in establishing that foundation — at the earliest and most capital-efficient stage of the company's development.
Investment Rationale
Investor Access
The best first step is a short introductory call. The overview flyer and full investor deck are available on request; the data room follows a call and a mutual NDA.
A comprehensive overview of Aedion Therapeutics, the VMD55 programme, and the investment case. Prepared for institutional investors and strategic partners considering initial engagement.
Detailed due diligence materials for qualified institutional investors and strategic partners at the formal review stage. Access is arranged following a short introductory call and a mutual NDA.
Next Steps
Aedion Therapeutics is currently accepting enquiries from institutional investors, strategic partners, and specialist healthcare funders. We are happy to arrange an introductory call, share the Overview Flyer, or — for parties ready to proceed to formal due diligence — provide access to the Data Room under NDA.